TTM
$17.27B
YoY change
+9.9%
5Y CAGR
+22.7%
Peak year (2025)
$28.26B
Cumulative EBITDA
$410.14B
EBITDA history chart for Merck & Co. (MRK) from 1985 to 2025
Latest: $28.26B
EBITDA growth chart for Merck & Co. (MRK) from 1985 to 2025
Latest: +9.9%
EBITDA history table for Merck & Co. (MRK) from 1985 to 2025
| 2025 | $28.26B | +9.9% | +$2.56B | ||
| 2024 | $25.71B | +272.2% | +$18.80B | ||
| 2023 | $6.91B | -67.6% | −$14.41B | ||
| 2022 | $21.32B | +19.1% | +$3.42B | ||
| 2021 | $17.90B | +75.8% | +$7.72B | ||
| 2020 | $10.18B | -10.5% | −$1.19B | ||
| 2019 | $11.37B | -18.7% | −$2.62B | ||
| 2018 | $13.99B | +17.1% | +$2.04B | ||
| 2017 | $11.95B | +10.4% | +$1.13B | ||
| 2016 | $10.82B | -13.1% | −$1.63B | ||
| 2015 | $12.45B | -49.6% | −$12.26B | ||
| 2014 | $24.71B | +85.3% | +$11.37B | ||
| 2013 | $13.33B | -18.8% | −$3.10B | ||
| 2012 | $16.43B | +6.3% | +$975.00M | ||
| 2011 | $15.46B | +58.5% | +$5.71B | ||
| 2010 | $9.75B | -46.8% | −$8.58B | ||
| 2009 | $18.33B | +55.1% | +$6.51B | ||
| 2008 | $11.81B | +55.3% | +$4.21B | ||
| 2007 | $7.61B | +27.7% | +$1.65B | ||
| 2006 | $5.96B | -21.3% | −$1.61B | ||
| 2005 | $7.57B | -7.8% | −$642.00M | ||
| 2004 | $8.21B | -16.9% | −$1.67B | ||
| 2003 | $9.88B | -4.2% | −$437.50M | ||
| 2002 | $10.32B | -0.9% | −$90.10M | ||
| 2001 | $10.41B | -2.6% | −$274.90M | ||
| 2000 | $10.69B | +18.0% | +$1.63B | ||
| 1999 | $9.06B | +22.5% | +$1.67B | ||
| 1998 | $7.39B | +10.3% | +$690.30M | ||
| 1997 | $6.70B | +13.3% | +$789.00M | ||
| 1996 | $5.91B | +12.3% | +$649.00M | ||
| 1995 | $5.26B | -0.3% | −$17.80M | ||
| 1994 | $5.28B | +22.8% | +$980.20M | ||
| 1993 | $4.30B | +12.8% | +$487.50M | ||
| 1992 | $3.81B | +13.0% | +$439.40M | ||
| 1991 | $3.37B | +16.1% | +$468.10M | ||
| 1990 | $2.91B | +18.2% | +$447.40M | ||
| 1989 | $2.46B | +18.6% | +$386.30M | ||
| 1988 | $2.07B | +31.2% | +$492.50M | ||
| 1987 | $1.58B | +27.9% | +$344.10M | ||
| 1986 | $1.24B | +20.8% | +$212.80M | ||
| 1985 | $1.02B | — | — |
- 2025$28.26B+9.9%
- 2024$25.71B+272.2%
- 2023$6.91B-67.6%
- 2022$21.32B+19.1%
- 2021$17.90B+75.8%
- 2020$10.18B-10.5%
- 2019$11.37B-18.7%
- 2018$13.99B+17.1%
- 2017$11.95B+10.4%
- 2016$10.82B-13.1%
- 2015$12.45B-49.6%
- 2014$24.71B+85.3%
- 2013$13.33B-18.8%
- 2012$16.43B+6.3%
- 2011$15.46B+58.5%
- 2010$9.75B-46.8%
- 2009$18.33B+55.1%
- 2008$11.81B+55.3%
- 2007$7.61B+27.7%
- 2006$5.96B-21.3%
- 2005$7.57B-7.8%
- 2004$8.21B-16.9%
- 2003$9.88B-4.2%
- 2002$10.32B-0.9%
- 2001$10.41B-2.6%
- 2000$10.69B+18.0%
- 1999$9.06B+22.5%
- 1998$7.39B+10.3%
- 1997$6.70B+13.3%
- 1996$5.91B+12.3%
- 1995$5.26B-0.3%
- 1994$5.28B+22.8%
- 1993$4.30B+12.8%
- 1992$3.81B+13.0%
- 1991$3.37B+16.1%
- 1990$2.91B+18.2%
- 1989$2.46B+18.6%
- 1988$2.07B+31.2%
- 1987$1.58B+27.9%
- 1986$1.24B+20.8%
- 1985$1.02B—
EBITDA values are taken from Merck & Co.'s reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EBITDA at Merck & Co. (MRK)
According to Merck & Co.'s latest reported financial statements, the company's current EBITDA (TTM) is $17.27B. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
2025's annual EBITDA for Merck & Co. (MRK) came in at $28.26B – grew 9.9% year-over-year.
Merck & Co. EBITDA compound annual growth for the 2020–2025 (5 years) window is +22.7%, sustaining 2 straight years of year-over-year growth.
The record annual EBITDA stands at $28.26B, reached in 2025; the historical low of $1.02B was recorded in 1985.
Merck & Co. EBITDA by Year
Merck & Co. EBITDA 2025: $28.26B
Merck & Co. EBITDA in 2025 was $28.26B, grew 9.9% from 2024. This figure represents the highest annual value in the available history.
Merck & Co. EBITDA 2024: $25.71B
2024's EBITDA for Merck & Co. came in at $25.71B, surged 272.2% from 2023.
Merck & Co. EBITDA 2023: $6.91B
Merck & Co. posted EBITDA of $6.91B in 2023, plunged 67.6% below 2022.
Merck & Co. EBITDA 2022: $21.32B
In 2022, Merck & Co. reported EBITDA of $21.32B, grew 19.1% from 2021.
Merck & Co. EBITDA 2021: $17.90B
Merck & Co. EBITDA in 2021 was $17.90B.
See more financial history for Merck & Co. (MRK).
Sector peers by EBITDA
Healthcare peers of Merck & Co. (MRK), ranked by their latest EBITDA
| $41.05B | |
| $27.94B | |
| $24.43B | |
| $23.06B | |
| $19.83B | |
| $17.63B | |
| $16.90B | |
| $11.47B |
- $41.05B
- $27.94B
- $24.43B
- $23.06B
- $19.83B
- $17.63B
- $16.90B
Frequently asked questions
Merck & Co. (MRK) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation